Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785843 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07785843 · ClinicalTrials.gov record · last posted 2026-08-25

A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers want to learn if V503 (also called the 9-valent human papillomavirus \[9vHPV\] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously received the bivalent HPV (2vHPV) vaccine. The 9vHPV vaccine protects against diseases caused by 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58) and the 2vHPV vaccine protects against diseases caused by 2 types of HPV (16 and 18). The goals of the trial are to learn: * If the 9vHPV vaccine can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in participants who received the 2vHPV vaccine * About the safety of the 9vHPV vaccine in prior 2vHPV vaccine recipients
Trial Details
NCT Number NCT07785843
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Papillomavirus Infections
Enrollment 930 participants
Start Date 2026-09-23
Primary Completion 2027-12-18 (estimated)
Study Completion 2028-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-25